search
Back to results

Elmex Gel Efficacy in Preventing White Spot Lesions

Primary Purpose

Dental Caries

Status
Unknown status
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
elmex gel
Sponsored by
Hadassah Medical Organization
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Dental Caries focused on measuring amine fluoride, white spot lesions, qlf

Eligibility Criteria

10 Years - 60 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: treatment plan: minimum of 10 teeth to be bonded labially at least 10 years old written declaration of informed consent Exclusion Criteria: known allergy to components of test products handicapped patients who have difficulties brushing their teeth pathological desquamation changes known pregnancy, breast feeding eating disorders disease that effect dental hard tissue participation in another clinical trial either currently or within the lase 30 days

Sites / Locations

  • Charite UniversityRecruiting
  • Hadassah Medical Organization, Jerusalem, IsraelRecruiting

Outcomes

Primary Outcome Measures

time and frequency of visually detected WSL (white spot lesions)

Secondary Outcome Measures

mineral loss according to QLF readings
Frequency and chronoloy of WSL

Full Information

First Posted
December 21, 2005
Last Updated
February 17, 2009
Sponsor
Hadassah Medical Organization
Collaborators
Gaba International AG
search

1. Study Identification

Unique Protocol Identification Number
NCT00268138
Brief Title
Elmex Gel Efficacy in Preventing White Spot Lesions
Official Title
Phase 4 Study Prevention of Incipient Carious Lesions (White Spot Lesions) in Patients With Fixed Orthodontic Appliances Following the Application of Elmex Gel
Study Type
Interventional

2. Study Status

Record Verification Date
December 2005
Overall Recruitment Status
Unknown status
Study Start Date
April 2006 (undefined)
Primary Completion Date
December 2010 (Anticipated)
Study Completion Date
December 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Hadassah Medical Organization
Collaborators
Gaba International AG

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
the objective of this phase IV study: to establish the efficacy of elmex gel with a fluoride concentration of 1.25% compared with placebo by determining prevention of white spot lesions in patients wearing fixed orthodontic appliances.
Detailed Description
314 healthy subjects undergoing orthodontic treatment will be examined. follow up will take place from bonding the appliance till debonding, at least 12 months and no more than 30 months. tooth brushing with product (test product or control) once per week during the entire study. 4 times a year additional tray application of test product or control. subjects wiil clean their teeth with the toothpaste they usually use during the entire study. toothbrush and a sandglass will be provided every 6 weeks

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dental Caries
Keywords
amine fluoride, white spot lesions, qlf

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
314 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
elmex gel
Other Intervention Name(s)
fluoride
Intervention Description
elmex gel once a week
Primary Outcome Measure Information:
Title
time and frequency of visually detected WSL (white spot lesions)
Time Frame
3 month
Secondary Outcome Measure Information:
Title
mineral loss according to QLF readings
Time Frame
3 month
Title
Frequency and chronoloy of WSL
Time Frame
3 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: treatment plan: minimum of 10 teeth to be bonded labially at least 10 years old written declaration of informed consent Exclusion Criteria: known allergy to components of test products handicapped patients who have difficulties brushing their teeth pathological desquamation changes known pregnancy, breast feeding eating disorders disease that effect dental hard tissue participation in another clinical trial either currently or within the lase 30 days
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea Engl, Dr.
Phone
++41614156056
Email
a.engl@gaba.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Meir Redlich, DMD PhD
Organizational Affiliation
Hadassah Medical Center, Dept of Orthodontics
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Paul George Jost-Brinkmann, Prof
Organizational Affiliation
Charite - Berlin, Dept of Orthodontics, Center of Dentistry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Charite University
City
Berlin
ZIP/Postal Code
D-13353
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul-Georg Jost-Brinkmann, Prof
Phone
++4930450562532
Email
paul-g.jost-brinkmann@charite.de
Facility Name
Hadassah Medical Organization, Jerusalem, Israel
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arik tzukert, DMD
Phone
00 972 2 6776095
Email
arik@hadassah.org.il
First Name & Middle Initial & Last Name & Degree
Hadas Lemberg, Phd
Phone
00 972 2 6777572
Email
lhadas@hadassah.org.il
First Name & Middle Initial & Last Name & Degree
Meir Redlich, DMD PhD

12. IPD Sharing Statement

Learn more about this trial

Elmex Gel Efficacy in Preventing White Spot Lesions

We'll reach out to this number within 24 hrs